ReviewDermatologic therapy
Is there truly a risk of lymphoma from biologic therapies?
Review in Dermatologic therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Golimumab and malignancies: true or false association?Medical oncology (Northwood, London, England) · 2011Pooled it
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Journal of the American Academy of Dermatology · 2011Pooled it
- What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.American journal of clinical dermatology · 2024Review
- Flare-up of cytokines in rheumatoid arthritis and their role in triggering depression: Shared common function and their possible applications in treatment (Review).Biomedical reports · 2021Review
- Adult intussusception secondary to an appendiceal tumour in a patient with ulcerative colitis: a case report.Surgical case reports · 2020Article
- Clinical Characteristics of 18 Patients with Psoriasis and Multiple Myeloma Identified Through Digital Health Crowdsourcing.Dermatology and therapy · 2020Article
- Spinal non-Hodgkin's lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature.Clinical rheumatology · 2016Review
- Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).The British journal of dermatology · 2014Article
- Malignant melanoma of the ileo-anal pouch anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case.European journal of medical research · 2013Article
- Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013Article
- Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.Journal of the National Cancer Institute · 2012Article
- TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?International journal of rheumatology · 2012Article
- Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.The British journal of dermatology · 2010Article
- Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. Biologics are generally safe and well tolerated. However, there has been concern over the risk of lymphoma with use of these agents because of their immunosuppressive properties. This review summarizes the current evidence in regards to lymphoma risk with biologic therapy obtained from case reports and case series, observational studies, clinical trials, and meta-analyses. The majority of data for T-cell inhibitors comes from case reports and relatively small, short-term clinical trials. In addition to published case reports and case series, TNF-alpha inhibitors have also been studied extensively in large cohort studies and meta-analyses of clinical trials derived primarily from the rheumatoid arthritis population. Current data are neither sufficient to completely rule out an increased risk of lymphoma associated with biologics, nor to firmly establish a causal relationship between biologics and lymphoma. Short- to intermediate-term treatment with biologics (e.g., up to 4 years) appears to be very safe with respect to lymphoma risk, especially with TNF-alpha inhibitors in which their potential risks appear to be well defined. Continued vigilance is warranted; however, in the appropriate patient, the risk-to-benefit profile of psoriasis treatment with respect to lymphoma risk appears highly favorable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.